DISCLAIMER: FOR EDUCATIONAL PURPOSES ONLY. CONSULT A HEALTHCARE PROFESSIONAL BEFORE ADMINISTERING ANY MEDICATION.
Peptides+ Chart

Tirzepatide Reconstitution & Dosage Calculator

Calculate Tirzepatide reconstitution and weekly dosing. Dual agonist (GLP-1/GIP) peptide calculator with proper titration schedule from 2.5mg to 15mg.

Tirzepatide

Calculate Tirzepatide reconstitution and weekly dosing. Dual agonist (GLP-1/GIP) peptide calculator with proper titration schedule from 2.5mg to 15mg.

mL

For research purposes only. Tirzepatide is a prescription medication (Mounjaro/Zepbound). Always work with a licensed healthcare provider.

Visual Syringe Guide

Use this interactive syringe visualization to verify your calculated dose. Enter the volume from your calculation above to see exactly where the plunger should land.

Syringe Configuration

mL
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Administration Note

For a 0.50 mL dose, pull the plunger back until the top ring of the black stopper aligns with the corresponding mark.

Volume Match0.50 mL

Important Disclaimer

For research purposes only. Tirzepatide is a prescription medication (Mounjaro/Zepbound). Always work with a licensed healthcare provider.

About This Calculator

Tirzepatide is a dual GLP-1/GIP receptor agonist. This calculator helps determine precise reconstitution ratios and dosing volumes following standard titration protocols.

How It Works

Enter your vial size, the amount of bacteriostatic water for reconstitution, and select your target weekly dose based on your titration phase. The calculator provides the exact volume needed per injection.

Frequently Asked Questions

Tirzepatide is a dual agonist (GLP-1 + GIP) while Semaglutide is a single GLP-1 agonist. The dual mechanism may provide different metabolic effects.
Clinical Review
Dr. Igor I. Bussel
Dr. Igor I. Bussel, MD
Board-Certified Ophthalmologist

Dr. Igor I. Bussel is a board-certified ophthalmologist and fellowship-trained surgeon affiliated with the University of California, Irvine (UCI), the Gavin Herbert Eye Institute, and the UCI School of Medicine.

Last Updated: 2026-01-06
Medically Reviewed
Evidence-Based
Updated 2026-01-06